UI - 11939818
AU - Grilli R; Soriano L; Farina C; Martin L; Requena L
Cutaneous eruption limited to skin covered by a swimming suit: mycosis
SO - Arch Dermatol 2002 Apr;138(4):527-32
AD - Fundacion Jimenez Diaz, Madrid, Spain.
UI - 11939819
AU - Hoefer HF; Chen SH; Duvic MA; Raimer SS
Alopecia, hypohidrosis, and ulcerations in a man: mycosis fungoides.
SO - Arch Dermatol 2002 Apr;138(4):527-32
AD - University of Texas Medical Branch, Galveston, TX, USA.
UI - 11939825
AU - Giuliani M; Mastroianni A; Di Carlo A; Donati P; Miceli M; Monini P;
Onset of non-AIDS Kaposi sarcoma during therapy with interferon alfa-2a
in an 82-year-old man with concomitant cutaneous T-cell lymphoma.
SO - Arch Dermatol 2002 Apr;138(4):535-7
UI - 11899124
AU - Mimouni D; David M; Feinmesser M; Coire CI; Hodak E
Vitiligo-like leucoderma during photochemotherapy for mycosis fungoides.
SO - Br J Dermatol 2001 Dec;145(6):1008-14
AD - Department of Dermatology, Rabin Medical Centre, Petah Tikva, Israel.
We describe four patients with mycosis fungoides (MF) in whom
depigmentation, and also leucotrichia in one, occurred following the
resolution of the eruption during phototherapy (psoralen plus
ultraviolet A treatment in three patients, climatotherapy in one). In
all cases, the depigmentation was localized to the area of the
pre-existing MF lesions. There was no clinically obvious phototoxicity.
Biopsy study including S100 staining in all cases, and electron
microscopy in one case, demonstrated the total absence of melanocytes,
with no evidence of MF. It is suggested that the phototherapy may have
activated a cell-mediated immunity leading to destruction of the
melanocytes. We recommend that vitiligo-like leucoderma be added to the
list of untoward effects of phototherapy in MF.
UI - 11899134
AU - Dereure O; Portales P; Clot J; Guilhou JJ
Decreased expression of fas (APO-1/CD95) on lesional CD4+ T lymphocytes
in cutaneous T cell lymphomas: correlations with blood data.
SO - Br J Dermatol 2001 Dec;145(6):1031-2
UI - 11937927
AU - Grange F; Bagot M
[Prognosis of primary cutaneous lymphomas]
SO - Ann Dermatol Venereol 2002 Jan;129(1 Pt 1):30-40
AD - Service de Dermatologie, Hopital Pasteur, 68024 Colmar Cedex, France.
INTRODUCTION: The assessment of prognosis is a major step in the
management of primary cutaneous lymphomas, as it allows to give patients
an accurate information and it directs the treatment choice. MATERIAL
AND METHODS: We performed a literature review of global prognosis and
prognostic factors in primary cutaneous lymphomas. We used survival as
the main endpoint, in particular specific survival and relative survival
which provide accurate estimates of lymphoma-related deaths. Independent
prognostic factors identified by multivariate survival analyses were
emphasized. RESULTS: Overall prognosis of mycosis fungoides has improved
during the past decades, possibly because of an increased proportion of
cases diagnosed at early stages. Five-year disease-specific or relative
survival rates of patients with T1 stage (patch/plaque disease<10 p. 100
of total skin surface), T2 (> 10 p. 100), T3 (tumor stage) and T4
(generalized erythroderma) are 100 p. 100, 67 to 96 p. 100, 51 to 80 p.
100 and 41 p. 100 respectively. Lymphomatoid papulosis and CD30+ primary
cutaneous large T-cell lymphomas have an excellent prognosis, with
5-year survival rates of 100 p. 100 and 96 p. 100 respectively.
CD30-negative primary cutaneous large T-cell lymphomas have an
aggressive clinical behavior (5-year disease-specific or relative
survival: 15 to 21 p. 100). Among primary cutaneous B-cell lymphomas,
immunocytomas and marginal-zone B-cell lymphomas are not
life-threatening. Follicle center-cell lymphomas that arise on the head
and trunk have also an indolent clinical course (5-year specific
survival rates: 94 to 97 p. 100). However, few of these lymphomas are
composed of more than 50 p. 100 of large cells with round nuclei
(centroblasts and/or immunoblasts) and may have a more aggressive
clinical course (5-year specific survival: 72 p. 100). Large B-cell
lymphomas of the leg often occur in older patients and have a poorer
prognosis (5-year specific survival rate: 52 p. 100). Cases with a
single lesion and those with a predominance of large cleaved cells
(large centrocytes) have a more favorable clinical course than those
with multiple tumors or a round cell morphology. CONCLUSION: Clinical,
histological and immunophenotypical prognostic factors which have been
identified so far may reliably predict the survival outcome in primary
cutaneous lymphomas. On this basis, therapeutic guidelines have been
proposed. These prognostic data will have to be taken into account when
evaluating new potential prognostic factors (e.g. immunophenotypic or
molecular) and performing prospective clinical trials.
UI - 9261475
AU - Dommann SN; Dommann-Scherrer CC; Ziegler T; Meyer J; Trueb RM; Kundig T;
Panizzon R; Burg G
Expression of intercellular adhesion molecule 3 (CDw50) on endothelial
cells in cutaneous lymphomas. A comparative study between nodal and
SO - Am J Dermatopathol 1997 Aug;19(4):391-5
AD - Department of Dermatology, University Hospital of Zurich, Switzerland.
Advances in the molecular definition of surface proteins (adhesion
molecules) involved in tumor metastasis may help to explain the invasive
behavior of malignant tumors, that is, the migration of tumor cells
involving reversible adhesive contacts, their release in the
circulation, and their extravasation into distant sites. Intercellular
adhesion molecule-3 (ICAM-3), the third receptor for the lymphocyte
function-associated antigen molecule-1 (LFA-1) was recently
characterized. We investigated fresh frozen skin biopsies from 10
patients with mycosis fungoides, four with pleomorphic T-cell lymphoma,
six with Sezary syndrome, 10 with primary cutaneous B-cell lymphoma, and
10 with eczematous lesions as controls. The biopsies were compared with
lymph node biopsies of five patients with known cutaneous T-cell
lymphoma (CTCL), 10 with primary nodal B-cell lymphoma, and 11 with
lymph-node specimens showing dermatopathic lymphadenopathy as controls.
The specimens were stained with ICAM-3 antibody (Bender Medical Science)
using the alkaline phosphatase antialkaline phosphatase method. Using
cytomorphologic criteria, neoplastic lymphocytes could be differentiated
from smaller reactive cells. Staining intensities were classified
semiquantitatively as follows: 4, strong expression in 75 to 100% of the
tumor cells; 3, 50 to 75%; 2, 25 to 50%; 1, 5 to 25%; and 0 fewer than
5% of the tumor cells. The endothelial cells in skin biopsies of seven
of 30 primary cutaneous lymphomas expressed ICAM-3. In contrast, no
expression of ICAM-3 could be demonstrated on endothelial cells in lymph
nodes infiltrated with tumor cells of CTCL. Finally, endothelial cells
of lymph nodes infiltrated with primary nodal B-cell lymphomas showed
expression of ICAM-3 in three of 10 patients. The endothelial cells in
the 11 control patients presenting with both eczematous lesions and
dermatopathic lymphadenopathy showed no staining for ICAM-3. Every
patient who expressed ICAM-3 on endothelial cells showed systemic spread
of this disease. The findings suggest that ICAM-3 expression may be
induced on endothelial cells in late-stage cutaneous lymphomas, probably
by a cytokine-mediated mechanism.
UI - 10911802
AU - ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Pulford K; Willemze R;
Falini B; Chott A; Meijer CJ
ALK expression in extranodal anaplastic large cell lymphoma favours
systemic disease with (primary) nodal involvement and a good prognosis
and occurs before dissemination.
SO - J Clin Pathol 2000 Jun;53(6):445-50
AD - Department of Pathology, University Hospital Vrije Universiteit,
Amsterdam, The Netherlands.
AIMS: In anaplastic large cell lymphoma (ALCL), the site of origin has
been described as an important prognostic factor. Recently, a fusion
protein containing anaplastic lymphoma kinase (ALK) was described in
systemic nodal ALCL, and shown to be associated with a good prognosis.
The aims of this study were to investigate whether the presence of ALK
protein differs between ALCL of different sites of origin; to determine
whether ALK expression occurs before dissemination to other sites; and,
finally, to investigate whether the site of origin remains a prognostic
parameter in ALK negative ALCL. METHODS: ALK expression, as detected by
immunohistochemistry using the monoclonal antibodies ALK1 and ALKc, was
studied in 85 ALCLs from different sites of origin. In 22 patients, ALK
expression was studied in multiple biopsies from different sites
(including 13 skin, 16 lymph node, and nine other). Overall survival
time was analysed using the Kaplan Meier method. RESULTS: ALK expression
was found in 20 of 51 systemic ALCLs with (primary) nodal involvement.
No ALK expression was found in 15 primary cutaneous, 14
gastrointestinal, and five nasal ALCLs. Multiple and subsequent biopsies
of patients showed ALK expression to be identical to that seen in the
primary diagnostic biopsy. Kaplan Meier survival curves showed that in
ALK negative ALCLs originating from different sites, primary cutaneous
cases are associated with an excellent overall survival, whereas the
other cases show a comparable five years survival of less than 40%.
CONCLUSIONS: If present, ALK expression favours systemic ALCL with
(primary) nodal involvement, and can be used in differentiating between
extranodal involvement of systemic (nodal) ALCL and primary extranodal
ALCL. ALK is expressed consistently in multiple biopsies of a given
patient, indicating that the chromosomal abnormality leading to aberrant
ALK expression occurs before dissemination to other sites. Finally, in
ALK negative non-cutaneous ALCLs, different sites of origin show
comparable poor survival.
UI - 11376029
AU - ten Berge RL; Oudejans JJ; Dukers DF; Meijer CJ
Anaplastic large cell lymphoma: what's in a name?
SO - J Clin Pathol 2001 Jun;54(6):494-5
UI - 11992182
AU - Abd-el-Baki J; Demierre MF; Li N; Foss FM
Transformation in mycosis fungoides: the role of methotrexate.
SO - J Cutan Med Surg 2002 Mar-Apr;6(2):109-16
AD - Department of Dermatology, Boston University School of Medicine, 720
Harrison Avenue, Boston, MA 02118, USA.
BACKGROUND: Large cell transformation in patients with mycosis fungoides
(MF) has been well reported in the literature. Although the risk factors
have not been clearly elucidated, advanced stage seems to be associated
with a higher incidence of transformation. Because MF is a rare
disorder, little is known about the influence of other factors such as
immunosuppressive therapy in the occurrence of transformation.
OBJECTIVE: We questioned the role of methotrexate (MTX) in the
transformation of MF to large cell lymphoma (LCL). METHODS: We
identified all patients with MF who were registered in our cutaneous
lymphoma database. Transformation was defined by the presence of large
cells exceeding 25% of the infiltrate in at least one skin biopsy. In
one patient, we followed the histologic, immunophenotypic, and genotypic
changes taking place as transformation occurred. Results: A total of 134
patients with MF were identified. Of 21 patients who received MTX, 3
transformed, and of the 113 patients in the non-MTX group, only 2
transformed. The incidence of transformation in the patients who
received MTX was significantly higher than in those who did not receive
the drug (14.3% vs. 1.8%; p = 0.03). This significance was maintained,
even after controlling for stage and sex. For one patient who
transformed, we demonstrated an identical dominant T-cell clone in all
skin specimens, including the large cell lymphoma. CONCLUSION: Our
results demonstrate a significant association between MTX exposure and
transformation to LCL in patients with MF. In light of the small sample
size, short followup of patients, and the inherent tendency of mycosis
fungoides to transform, the role for MTX in transformation is unproven
and needs to be confirmed in a multicenter study.
UI - 11887483
AU - Meyer KM
Incidence of CTCL in Vietnam veterans.
SO - Dermatol Nurs 2002 Feb;14(1):42, 45, 52
AD - Photopheresis Unit, Morristown Memorial Hospital, Morristown, NJ, USA.
The causative factors of cutaneous T-cell lymphoma (CTCL) are unclear.
Exposure to herbicides has been linked to the development of other
lymphomas. Three Vietnam Veterans with CTCL treated at a photopheresis
unit in New Jersey report positive histories of exposure to Agent
Orange, a herbicide used during the war.
UI - 11887485
AU - Musse L
Cutaneous T-cell lymphoma.
SO - Dermatol Nurs 2002 Feb;14(1):55
AD - Dermatology Clinic, National Institutes of Health, Bethesda, MD, USA.
The "Clinical Snapshot" series provides a concise examination of a
clinical presentation including history, treatment, patient education,
and nursing measures. Using the format here, you are invited to submit
your "Clinical Snapshot" to Dermatology Nursing.
UI - 11920262
AU - Bachelez H
Is there a role for epigenetic factors in the pathogenesis of
epidermotropic cutaneous T-cell lymphomas (mycosis fungoides and Sezary
SO - Hematol J 2001;2(4):286-9
AD - Skin Research Insitute, Unite INSERM U532, Saint-Louis University
Hospital, Assistance Publique-Hopitauz de Paris, Paris, France.
UI - 11937737
AU - Marzano AV; Borghi A; Facchetti M; Alessi E
Ichthyosiform mycosis fungoides.
SO - Dermatology 2002;204(2):124-9
AD - Institute of Dermatological Sciences of the University of Milan and
IRCCS Ospedale Maggiore of Milan, Italy. email@example.com
BACKGROUND: Mycosis fungoides (MF) is a skin malignancy of T helper
lymphocytes with a wide clinical spectrum. Among the atypical variants
of MF, there is an ichthyosis-like presentation. However, to date, only
1 case of ichthyosiform MF has been reported. OBJECTIVE: Our goal was to
summarize the clinical characteristics and course, and the pathological,
immunohistochemical and molecular genetic findings on 4 patients with
ichthyosiform MF. METHODS: A retrospective study was conducted. RESULTS:
The 4 patients represented 1.8% of the 221 patients with MF seen by us
since 1975. None progressed to systemic disease in up to 12 years
(median, 10 years) after the onset of the cutaneous manifestations.
Interestingly, skin lesions typical of so-called follicular MF (FMF)
were associated in 3 of 4 cases, whereas cutaneous manifestations of
classic MF were absent in all 4 patients. CONCLUSION: Ichthyosiform MF
represents a rare variant within the clinicopathologic spectrum of MF
usually featuring a benign course and a tendency to be associated with
lesions of FMF but not with lesions of classic MF. Copyright 2002 S.
Karger AG, Basel
UI - 11952703
AU - Chang SE; Lee SY; Choi JH; Sung KJ; Moon KC; Koh JK
Cutaneous dissemination of nasal NK/T-cell lymphoma with bone marrow,
liver and lung involvement.
SO - Clin Exp Dermatol 2002 Mar;27(2):120-2
AD - Department of Dermatology, Asan Medical Center, College of Medicine,
University of Ulsan, 388-1 Poongnap-dong, Songpa-gu, Seoul 138-736,
We describe a 32-year-old Korean man with a primary nasal natural killer
(NK)/T-cell lymphoma (NKTCL). Combination chemotherapy and radiotherapy
resulted in initial complete remission. However, cutaneous dissemination
to the trunk and proximal extremities occurred 16 months later and
further investigations revealed involvement of the liver, lymph nodes,
lung and bone marrow. Nasal CD56+ NKTCL is mostly localized to the nasal
area but also shows a predilection for other sites, such as skin.
Cutaneous dissemination may be an indicator of widespread metastasis to
internal organs and is consistently fatal.
UI - 11978140
AU - Apisarnthanarax N; Talpur R; Duvic M
Treatment of cutaneous T cell lymphoma: current status and future
SO - Am J Clin Dermatol 2002;3(3):193-215
AD - Division of Internal Medicine, Department of Dermatology, University of
Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX
The treatment of cutaneous T cell lymphoma (CTCL), which includes
mycosis fungoides and Sezary syndrome, has been in a state of continual
change over recent decades, as new therapies are constantly emerging in
the search for more effective treatments for the disease. However,
prognosis and survival of patients with CTCL remains dependent upon
overall clinical stage (stage IA-IVB) at presentation, as well as
response to therapy. Past therapies have been limited by toxicity or the
lack of consistently durable responses, and few treatments have been
shown to actually alter survival, especially in the late stages of
disease. Even aggressive chemotherapy has not been shown to improve
overall survival compared to conservative sequential therapy in advanced
disease, and adds the risk of immunosuppressive complications. Over the
last decade, extracorporeal photopheresis has been the only single
treatment that has been shown to improve survival in patients with
Sezary syndrome, although its true efficacy and place in combination
therapy remain unclear. Much of the focus of current research has been
on combinations of skin-directed therapies and biological response
modifiers, which improve response rates. The results of various trials
over the years have also brought into favor the use of post-remission
maintenance therapy with topical corticosteroids, topical
mechlorethamine (nitrogen mustard), interferon-alpha, or phototherapy to
prevent disease relapse. Recent novel developments in CTCL therapy
include oral bexarotene, a retinoid X receptor-selective retinoid that
has activity in all stages of CTCL, and the topical gel formulation of
bexarotene, which plays a role in treating localized lesions. US Food
and Drug Administration (FDA)-approved, oral systemic bexarotene has the
advantage of a 48% overall response rate at a dosage of 300 mg/m(2)/day,
and avoids immunosuppression and risk of central line and
catheter-related infectious complications that are associated with other
systemic therapies. Monitoring of triglycerides and use of concomitant
lipid-lowering agents and thyroid replacement is required in most
patients. Also recently FDA-approved, denileukin diftitox is the first
of a novel class of fusion toxin proteins and is selective for
interleukin-2R (CD25+) T cells, targeting the malignant T cell clones in
CTCL. Denileukin diftitox is associated with capillary leak syndrome in
20 to 30% of patients, which may be ameliorated by hydration and
corticosteroids. Higher response rates are possible by combining
bexarotene with "statin" drugs and active CTCL therapies. Studies are
being conducted on combining bexarotene and denileukin diftitox with
other modalities. Biological response modifier therapies that are in
current or future investigational trials include topical tazarotene,
pegylated interferon, interleukin-2, and interleukin-12. At the
forefront of systemic chemotherapy development, pegylated liposomal
doxorubicin, gemcitabine, and pentostatin appear to have the greatest
potential for success in CTCL therapy. Bone marrow transplantation,
which is currently limited by the risk of graft-versus-host disease,
offers the greatest potential for disease cure. Further developments for
CTCL may include more selective immunomodulatory agents, vaccines, and
UI - 11696852
AU - do Valle AC; Galhardo MC; Leite AC; Araujo AQ; Cuzzi-Maya T; Maceira JP;
de Ameida Dobbin J
Adult T-cell leukemia/lymphoma associated with HTLV-1 infection in a
SO - Rev Inst Med Trop Sao Paulo 2001 Sep-Oct;43(5):283-6
AD - Centro de Pesquisa Hospital Evandro Chagas, Fundacao Oswaldo Cruz, Rio
de Janeiro, RJ, Brasil. firstname.lastname@example.org
We present the case of a 15-year-old patient infected with HTLV-1 who
developed a cutaneous T-cell lymphoma, confirmed by histopathological
and immunohistochemical examination, as well as clinically and
hematologically confirmed leukemia. The patient died 3 months after
initial presentation of the disease. The rarity of the disease in this
age group justifies the present report.
UI - 11929784
AU - Berger CL; Hanlon D; Kanada D; Dhodapkar M; Lombillo V; Wang N;
Christensen I; Howe G; Crouch J; El-Fishawy P; Edelson R
The growth of cutaneous T-cell lymphoma is stimulated by immature
SO - Blood 2002 Apr 15;99(8):2929-39
AD - Yale University, School of Medicine, Department of Dermatology and
Laboratory Medicine, New Haven, CT 06510, USA. email@example.com
In the initial stage of cutaneous T-cell lymphoma (CTCL), proliferating
CTCL cells are concentrated in the epidermis in close association with
an immature dendritic cell (DC), the Langerhans cell. Because long-term
in vitro culture of CTCL cells has proven difficult, the in vivo
association with the major antigen-presenting cell (APC) of the
epidermis has been postulated to play a role in directly stimulating the
clonal T-cell proliferation. We report that CTCL cells can be
reproducibly grown in culture for 3 months when cocultured with immature
DCs. CTCL cells retain the phenotype and genotype of the initial
malignant clone, whereas the APCs are a mixture of immature and mature
DCs. CTCL cell and DC survival was dependent on direct membrane contact.
Growth was inhibited by antibodies that bound to the T-cell receptor
(TCR) or interfered with the interaction of CD40 with its ligand on the
CTCL cell. Addition of antibody to CD3 or the clonotypic TCR caused
rapid CTCL cell apoptosis followed by engulfment by avidly phagocytic
immature DCs and subsequent DC maturation. The opportunity to study CTCL
cells and immature DCs for prolonged periods will facilitate studies of
tumor cell biology and will allow investigation of the intriguing
hypothesis that CTCL cell growth is driven through TCR recognition of
class II-presented self-peptides. In addition, the culture of CTCL cells
will permit evaluation of therapies in vitro before clinical
intervention, thereby improving safety and efficacy.
UI - 11966709
AU - Ling TC; Harris M; Craven NM
Epstein-Barr virus-positive blastoid nasal T/natural killer-cell
lymphoma in a caucasian.
SO - Br J Dermatol 2002 Apr;146(4):700-3
AD - Department of Dermatology, Burnley General Hospital, Burnley BB10 2PQ,
T/natural killer (NK)-cell lymphoma is a subtype of non-Hodgkin's
lymphoma, with frequent cutaneous involvement; it follows an aggressive
course. Most cases are reported in Asia, and typically present with
nasopharyngeal involvement. There is a distinct variant known as
blastoid T/NK-cell lymphoma, which affects elderly, non-Asian patients,
with absence of nasal involvement. We report a middle-aged caucasian man
who had blastoid T/NK-cell lymphoma with nasal involvement.
UI - 11986945
AU - Rappl G; Abken H; Muche JM; Sterry W; Tilgen W; Andre S; Kaltner H;
Ugurel S; Gabius HJ; Reinhold U
CD4+CD7- leukemic T cells from patients with Sezary syndrome are
protected from galectin-1-triggered T cell death.
SO - Leukemia 2002 May;16(5):840-5
AD - Department of Dermatology, The Saarland University Hospital, 66421
In early stages of cutaneous T cell lymphoma (Sezary syndrome) both
CD4+CD7- and CD4+CD7+ T cells clonally expand whereas in late stages of
the disease CD7- cells are predominant in number, giving rise to the
question whether CD7- T cells have a survival advantage in the skin.
Galectin-1, a cell-bound lectin, was recently reported to trigger
apoptosis in activated CD7+ T cells. Here, we demonstrate that in
contrast to activated CD7(+) T cells, quiescent and activated CD69+ CD7-
T cells from healthy donors and from Sezary patients are resistant to
galectin-1-mediated cell death. CD7- T cells are apoptosis-resistant
even during coculture with IFN-gamma-stimulated endothelial cells that
constitutively express galectin-1 in high amounts. These data imply that
resistance of CD7- T cells to galectin-1-induced apoptosis may
contribute to the accumulation of CD7- Sezary T cells during progression
of the disease.
UI - 12001911
AU - Zucker-Franklin D
The role of interleukin-7 and interleukin-15 in cutaneous T-cell
SO - Blood 2002 May 1;99(9):3488; discussion 3488-9
UI - 11977317
AU - Wojnowska D; Lecewicz-Torun B; Chodorowska G; Juszkiewicz-Borowiec M;
Expression of selected T-cell antigens in the skin infiltration in
primary cutaneous T-cell lymphomas.
SO - Ann Univ Mariae Curie Sklodowska [Med] 2001;56():237-42
AD - Department of Dermatology, Medical University of Lublin.
Skin biopsy specimens obtained from 16 patients with mycosis fungoides
(MF) were examined immunohistochemically to assess phenotype of T-cells.
Cases of benign chronic skin disorders (BCD) were included in control
group. Examination of skin biopsies obtained from patients with MF
revealed aberrant immunophenotypes of T-cells (loss of one or more of
T-cell markers CD7, CD5, CD8, and rarely CD3). The expression of CD1a
antigen both in the dermis and epidermis of the studied groups was
similar and normal. No correlation between this loss of antigenicity and
the prognosis was observed. These disturbances were seen in most of the
cases of the early MF, but not seen in inflammatory skin diseases. In
conclusion, the presence of aberrant immunophenotype of T-cells in skin
infiltration may be useful in the diagnosis and differentiation of MF.
UI - 10411410
AU - Plettenberg H; Stege H; Megahed M; Ruzicka T; Hosokawa Y; Tsuji T;
Morita A; Krutmann J
Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma.
SO - J Am Acad Dermatol 1999 Jul;41(1):47-50
AD - Department of Dermatology, Heinrich-Heine-University, Dusseldorf,
BACKGROUND: The results of a recent study suggested that ultraviolet A1
radiation (UVA1R; 340-400 nm) phototherapy for atopic dermatitis works
through induction of apoptosis in skin-infiltrating helper T cells,
indicating the possibility that other helper T cell-mediated skin
diseases may respond to UVA1R as well. OBJECTIVE: The purpose of this
open pilot study was to assess the therapeutic effectiveness of UVA1
phototherapy for cutaneous T-cell lymphoma (CTCL). METHODS: UVA1
phototherapy was used as monotherapy in patients (n = 3) with
histologically proven CTCL (stages IA and IB). For daily whole body UVA1
irradiations, either a high-dose (n = 2; 130 J/cm2 UVA1 per exposure) or
medium-dose (n = 1; 60 J/cm2 UVA1) regimen was used. Therapeutic
effectiveness was assessed clinically and histologically. RESULTS: In
each of the 3 patients, skin lesions began to resolve after only a few
UVA1 radiation exposures. Complete clearance was observed between 16 and
20 exposures, regardless of whether the high- or medium-dose regimen had
been employed. CONCLUSION: These studies suggest that patients with CTCL
stages IA and IB can be treated effectively with UVA1 phototherapy.
UI - 11050602
AU - Stander H; Schwarz T
Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma?
SO - J Am Acad Dermatol 2000 Nov;43(5 Pt 1):881
UI - 11963190
AU - Dueck D; Hermes B; Audring H; Kohl PK
[CD8-positive, CD30-negative cutaneous T-cell lymphoma simulating
SO - Hautarzt 2002 Feb;53(2):114-7
AD - Krankenhaus Neukolln, Abteilung fur Dermatologie und Venerologie,
Rudower Strasse 48, 12351 Berlin.
Ulcerated primary cutaneous lymphomas are not rare, but the clinical
manifestation as a pyoderma gangrenosum look-alike is extraordinary.
CD8-positive lymphomas are rare, unclassifiable tumours with variable
prognosis. We report on a 49-year-old patient with a large ulcerated
primary cutaneous lymphoma on the left chest wall presenting as pyoderma
gangrenosum. With immunohistochemical staining, most lymphocytes were
shown to be CD8-positive. The CD30 antigen was not expressed. After
radiotherapy with complete skin irradiation, the lymphoma regressed
completely. The patient has been free of relapse for 28 months so far.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.